I read a two articles about treatments for recurrence of rhabdomyosarcoma recently. I first got interested in this childhood and young adult cancer when I read Karen's blog. Karen was diagnosed as a young adult and wants to raise awareness for this rare cancer, sometimes just called rhabdo, that does not have a great survival rate. I did a post about her and her cancer journey that you can read called Raising awareness about rhabdomyosarcoma.

This brings me to the two articles that I recently read about treatments for recurrent rhabdomyosarcoma:

A Phase II clinical trial was published in the Journal of Clinical Oncology. The drug Camptosar (irinotecan) reduced or eliminated detectable cancer in 11 percent of the children who had relapsed rhabdomyosarcoma. The study states that patients with recurrent disease have a very poor prognosis. Eleven percent, (four out of thirty five patients), does not seem like a very high success rate however, these trials are needed to find treatments to improve survival for this deadly cancer.

The other article I read was also published in the Journal of Clinical Oncology. It states that treatment with the chemotherapy drug combination of Camptosar (irinotecan) and vincristine reduced or eliminated detectable cancer in 70 percent of children with metastatic rhabdomyosarcoma. It stated that treatment alone with Camptosar is not good enough. The combination of Camptosar and vincristine, 70 percent of children experienced a partial or complete disappearance of detectable cancer. This is better news!

You can read more about rhabdomyosarcoma in the post called Cancer by the Numbers: Rhabdomyosarcoma.

Patients diagnosed with retinoblastoma have a greater chance than the general public of developing soft-tissue sarcomas over their lifetime, says an article recently published in the Journal of the National Cancer Institute.

Retinoblastoma is a rare cancer that originates in the eye. Treatment for retinoblastoma often includes radiation therapy and may also include chemotherapy and surgical removal of the eye. There has been some concern that radiation therapy increases the risk of developing cancer in tissues within the radiation field.

The National Cancer Institute recently conducted a study to evaluate potential associates between patients diagnosed with retinoblastoma and the rate of soft-tissue sarcomas following treatment.

The study included 963 patients treated and diagnosed with hereditary retinoblastoma from 1914-1984. Data on these patients regarding the rates of soft-tissues sarcomas were compared to the general population.

The researchers concluded that patients diagnosed with hereditary retinoblastoma appear to have a significantly increased risk of developing soft-tissue sarcomas. This risk was increased in these patients whether or not they received radiation therapy and remained increased outside the field of radiation therapy; this indicates a potential genetic susceptibility for soft tissue sarcomas among patients with hereditary retinoblastoma.